CJ Bioscience
Develops microbiome therapeutics for oncology and IBD using an AI-powered platform.
311690 | KO
Overview
Corporate Details
- ISIN(s):
- KR7311690002
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 중구 세종대로 14 그랜드센트럴타워 B동 7층, 중구
- Website:
- https://www.cjbioscience.com/en/
Description
CJ Bioscience is a company focused on developing microbiome-based therapeutics to address unmet medical needs. It utilizes a proprietary AI-powered drug discovery platform, Ez-Mx®, to identify and advance novel live biotherapeutic products (LBPs). The company's primary focus is on creating treatments for complex diseases, with a pipeline targeting oncology and inflammatory bowel disease (IBD). Key candidates include CJRB-101, its lead oncology asset, and CJRB-201, a promising oral therapeutic for IBD that has demonstrated significant anti-inflammatory efficacy in preclinical models. In addition to its drug development programs, CJ Bioscience provides next-generation sequencing (NGS) and bioinformatics solutions to the global research community through its EzBioCloud platform.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-07-25 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.3 KB | ||
| 2023-07-06 00:00 |
유상증자1차발행가액결정
|
Korean | 8.2 KB | ||
| 2023-07-06 00:00 |
[기재정정]주요사항보고서(유상증자결정)
|
Korean | 32.7 KB | ||
| 2023-07-06 00:00 |
권리락(유상증자)
|
Korean | 3.5 KB | ||
| 2023-07-06 00:00 |
[발행조건확정]증권신고서(지분증권)
|
Korean | 161.9 KB | ||
| 2023-07-06 00:00 |
[기재정정]투자설명서
|
Korean | 2.3 MB | ||
| 2023-06-26 00:00 |
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2023-06-22 00:00 |
투자설명서
|
Korean | 2.1 MB | ||
| 2023-06-15 00:00 |
투자판단관련주요경영사항(임상시험계획승인신청등결정)(마이크로바이옴 면역항암치료제 CJRB-101의 한국 식품의약품안전처(MFDS) 제1/2상 임…
|
Korean | 15.7 KB | ||
| 2023-06-07 00:00 |
[기재정정]증권신고서(지분증권) (2023.08)
|
Korean | 2.2 MB | ||
| 2023-05-31 00:00 |
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 77.7 KB | ||
| 2023-05-22 00:00 |
주요사항보고서(유상증자결정)
|
Korean | 28.8 KB | ||
| 2023-05-22 00:00 |
증권신고서(지분증권) (2023.08)
|
Korean | 2.1 MB | ||
| 2023-05-15 00:00 |
분기보고서 (2023.03)
|
Korean | 1.3 MB | ||
| 2023-03-31 00:00 |
투자판단관련주요경영사항(마이크로바이옴 면역항암치료제 CJRB-101의 한국 식품의약품안전처(MFDS) 제1/2상 임상시험계획(IND) 신청)
|
Korean | 10.8 KB |
Automate Your Workflow. Get a real-time feed of all CJ Bioscience filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CJ Bioscience
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CJ Bioscience via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
